In de novo mPCa patients, we detected methylated ctDNA in 32.3% of the patients with low tumor volume and in 89.3% of patients with high tumor volume using the DOCK2, HAPLN3, and FBXO30 assays (positive for at least one assay). Here, HAPLN3 is linked to neoplasm.